BACKGROUND: Cervical tissue-based organ cultures have been used successfully to evaluate microbicides for toxicity and antiviral activity. The antimicrobial peptide retrocyclin RC-101 has been shown to have potent anti-HIV activity in cell culture. OBJECTIVE: To evaluate RC-101 in organ culture for toxicity and its ability to block HIV-1 transmission across cervical mucosa. METHODS: A cervical tissue-based organ culture was used to measure antiviral activity of RC-101. Cytotoxicity in tissues was determined by immunostaining of cellular proteins and by measuring inflammatory cytokines using real-time reverse transcriptase-polymerase chain reaction and Luminex technology. RESULTS: RC-101 blocked transmission of both R5 and X4 HIV-1 across cervical mucosa in this organ culture model. Furthermore, film-formulated RC-101 exhibited potent antiviral activity in organ culture. Such antiviral activity of RC-101 was retained in the presence of semen and vaginal fluid. RC-101 showed no cytotoxicity in cervical tissue. Furthermore, RC-101 did not induce proinflammatory cytokine response in tissues. RC-101 also did not have any effect on natural killer cell activity and proliferation of CD4 and CD8 cells and did not show chemotactic activity. CONCLUSIONS: Therefore, because of strong antiviral activity and low cytotoxicity in cervical tissues, RC-101 should be considered as an excellent microbicide candidate against HIV-1.
BACKGROUND: Cervical tissue-based organ cultures have been used successfully to evaluate microbicides for toxicity and antiviral activity. The antimicrobial peptide retrocyclin RC-101 has been shown to have potent anti-HIV activity in cell culture. OBJECTIVE: To evaluate RC-101 in organ culture for toxicity and its ability to block HIV-1 transmission across cervical mucosa. METHODS: A cervical tissue-based organ culture was used to measure antiviral activity of RC-101. Cytotoxicity in tissues was determined by immunostaining of cellular proteins and by measuring inflammatory cytokines using real-time reverse transcriptase-polymerase chain reaction and Luminex technology. RESULTS:RC-101 blocked transmission of both R5 and X4 HIV-1 across cervical mucosa in this organ culture model. Furthermore, film-formulated RC-101 exhibited potent antiviral activity in organ culture. Such antiviral activity of RC-101 was retained in the presence of semen and vaginal fluid. RC-101 showed no cytotoxicity in cervical tissue. Furthermore, RC-101 did not induce proinflammatory cytokine response in tissues. RC-101 also did not have any effect on natural killer cell activity and proliferation of CD4 and CD8 cells and did not show chemotactic activity. CONCLUSIONS: Therefore, because of strong antiviral activity and low cytotoxicity in cervical tissues, RC-101 should be considered as an excellent microbicide candidate against HIV-1.
Authors: Carsten Münk; Ge Wei; Otto O Yang; Alan J Waring; Wei Wang; Teresa Hong; Robert I Lehrer; Nathaniel R Landau; Alexander M Cole Journal: AIDS Res Hum Retroviruses Date: 2003-10 Impact factor: 2.205
Authors: Sherry M Owen; Donna L Rudolph; Wei Wang; Alexander M Cole; Alan J Waring; Renu B Lal; Robert I Lehrer Journal: AIDS Res Hum Retroviruses Date: 2004-11 Impact factor: 2.205
Authors: Alexander M Cole; Teresa Hong; Lee Ming Boo; Tung Nguyen; Chengquan Zhao; Greg Bristol; Jerome A Zack; Alan J Waring; Otto O Yang; Robert I Lehrer Journal: Proc Natl Acad Sci U S A Date: 2002-02-19 Impact factor: 11.205
Authors: J van De Wijgert; A Fullem; C Kelly; S Mehendale; S Rugpao; N Kumwenda; Z Chirenje; S Joshi; T Taha; N Padian; R Bollinger; K Nelson Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Phalguni Gupta; Kelly B Collins; Deena Ratner; Simon Watkins; Gregory J Naus; Daniel V Landers; Bruce K Patterson Journal: J Virol Date: 2002-10 Impact factor: 5.103
Authors: Rochelle K Rosen; Kathleen M Morrow; Alex Carballo-Diéguez; Joanne E Mantell; Susie Hoffman; Fang Gai; Lisa Maslankowski; Wafaa M El-Sadr; Kenneth H Mayer Journal: J Womens Health (Larchmt) Date: 2008-04 Impact factor: 2.681
Authors: Ronald S Veazey; Per Johan Klasse; Thomas J Ketas; Jacqueline D Reeves; Michael Piatak; Kevin Kunstman; Shawn E Kuhmann; Preston A Marx; Jeffrey D Lifson; Jason Dufour; Megan Mefford; Ivona Pandrea; Steven M Wolinsky; Robert W Doms; Julie A DeMartino; Salvatore J Siciliano; Kathy Lyons; Martin S Springer; John P Moore Journal: J Exp Med Date: 2003-11-17 Impact factor: 14.307
Authors: Colleen R Eade; Amy L Cole; Camila Diaz; Lisa C Rohan; Michael A Parniak; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole Journal: Am J Reprod Immunol Date: 2012-11-20 Impact factor: 3.886
Authors: Joseph A Fraietta; Yvonne M Mueller; Karissa L Lozenski; Deena Ratner; Alina C Boesteanu; Aidan S Hancock; Carol Lackman-Smith; Isaac J Zentner; Irwin M Chaiken; Suhman Chung; Stuart F J LeGrice; Beth A Snyder; Marie K Mankowski; Natalie M Jones; Jennifer L Hope; Phalguni Gupta; Sharon H Anderson; Brian Wigdahl; Peter D Katsikis Journal: Antimicrob Agents Chemother Date: 2014-09-15 Impact factor: 5.191